Magle Chemoswed Holding AB (SE:MAGLE)
:MAGLE
Want to see SE:MAGLE full AI Analyst Report?
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr3.68 - kr30.00
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.06K
Market Cap
kr92.92M
Enterprise Valuekr425.52M
Total Cash (Recent Filing)kr13.59M
Total Debt (Recent Filing)kr346.19M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.49
Shares Outstanding20,649,378
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-11.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr377.00M
Bulls Say, Bears Say
Bulls Say
Service + Manufacturing Business ModelMagle's dual contract development and manufacturing model creates diversified revenue streams and recurring client work. That structural mix supports steadier long-term cash flows and customer stickiness versus single-product developers, improving resilience across cycles.
Meaningful Equity CushionThe company retains a meaningful equity base relative to debt, providing a multi-year capital buffer. This equity cushion supports ongoing operations and investment while absorbing losses, giving management time to restore profitability without immediate insolvency pressure.
Prior Multi-year Revenue ExpansionHistoric growth across 2022–2024 indicates underlying market demand and execution capability. That prior momentum implies the company can scale its service/manufacturing offerings when operational issues resolve, supporting medium-term revenue recovery potential.
Bears Say
Swing To Negative ProfitabilityThe sharp transition from profit to negative EBIT and net income reduces retained earnings and limits reinvestment capacity. Persistent unprofitable operations can erode the equity base, force cost cutting, and undermine the firm's ability to compete on R&D and service quality over time.
Persistent Negative Operating And Free Cash FlowTwo consecutive years of negative operating cash flow and a ~54.8% deterioration in free cash flow indicate reduced internal funding. This raises refinancing and liquidity risk, constrains capital expenditures and working capital support, and increases dependence on external financing.
Rising Leverage And Reduced ResilienceHigher leverage combined with a shrinking equity cushion makes the balance sheet less resilient to shocks. Increased debt loads raise interest and covenant risk, limit flexibility for strategic investments, and heighten the chance that further losses impair solvency over the medium term.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr3.68 and its highest was kr30.00 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr92.92M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is May 18, 2026 which is in 17 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Mar 27, 2026. The company reported -kr6.491 earnings per share for the quarter, missing the consensus estimate of N/A by -kr6.491.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of N/A. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 20,649,378 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -kr6.491 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.042%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
Technical Analysis
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Corline Biomedical AB
―